GlyphAllo (allopregnanolone prodrug) vs KH607

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: GABA-A receptor · full Major Depressive Disorder pipeline

GlyphAllo (allopregnanolone prodrug) · SPT-300

Developed by Seaport Therapeutics and partners

Phase 2 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07065240 (registry estimate)

No aligned efficacy figure on record for this race.

KH607

Developed by Chengdu Kanghong Pharmaceutical

Phase 3 in Major Depressive Disordersmall molecule
Partial signal

NCT07101120 · Phase 2 · completed

The study was randomized, quadruple-blind and placebo-controlled, with 126 participants, and used the clinical HAM-D17 score as its primary endpoint. The sponsors reported on 15 May 2026 that the study met its primary endpoint; they released no effect size, and the registry has no posted results, so the evidence is moderate.

Result as reported by the sponsors (15 May 2026 release); no effect size released and no results posted on ClinicalTrials.gov.

Next expected readout: December 2027 · NCT07741240 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlyphAllo (allopregnanolone prodrug)KH607
MADRS, change (acute)—Not reported—Trial running · NCT07741240
CGI-S, change (acute)—Not reported—Trial running · NCT07741240
MADRS response—Not reported—Trial running · NCT07741240
MADRS remission—Not reported—Trial running · NCT07741240
Relapse (% of patients)—Not reported—Trial running · NCT07741240

MADRS, change (acute)

GlyphAllo (allopregnanolone prodrug)
—Not reported
KH607
—Trial running · NCT07741240

CGI-S, change (acute)

GlyphAllo (allopregnanolone prodrug)
—Not reported
KH607
—Trial running · NCT07741240

MADRS response

GlyphAllo (allopregnanolone prodrug)
—Not reported
KH607
—Trial running · NCT07741240

MADRS remission

GlyphAllo (allopregnanolone prodrug)
—Not reported
KH607
—Trial running · NCT07741240

Relapse (% of patients)

GlyphAllo (allopregnanolone prodrug)
—Not reported
KH607
—Trial running · NCT07741240
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

GlyphAllo (allopregnanolone prodrug): no structured comparison results are available for Major Depressive Disorder.

KH607: no structured comparison results are available for Major Depressive Disorder.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GlyphAllo (allopregnanolone prodrug)'s landscape · KH607's landscape